摘要
First-line chemotherapy for advanced/metastatic human epidermal growth factor receptor 2 (HER2)-negative gastric/gastroesophageal junction cancer (GC/GEJC) has poor median overall survival (OS; <1 year). We report efficacy and safety results from Chinese patients in the phase III global CheckMate 649 study of nivolumab plus chemotherapy vs chemotherapy for the first-line treatment of GC/GEJC/esophageal adenocarcinoma (EAC). Chinese patients with previously untreated advanced or metastatic GC/GEJC/EAC were randomized to receive nivolumab (360 mg Q3W or 240 mg Q2W) plus chemotherapy (XELOX [capecitabine and oxaliplatin] Q3W or FOLFOX [oxaliplatin, leucovorin and 5-fluorouracil] Q2W), nivolumab plus ipilimumab (not reported) or chemotherapy alone. OS, blinded independent central review-assessed progression-free survival (PFS), objective response rate (ORR), duration of response (DOR) and safety are reported. Of 1581 patients enrolled and randomized, 208 were Chinese. In these patients, nivolumab plus chemotherapy resulted in clinically meaningful improvement in median OS (14.3 vs 10.2 months; HR 0.61 [95% CI: 0.44-0.85]), median PFS (8.3 vs 5.6 months; HR 0.57 [95% CI: 0.40-0.80]), ORR (66% vs 45%) and median DOR (12.2 vs 5.6 months) vs chemotherapy, respectively. The safety profile was acceptable, with no new safety signals observed. Consistent with results from the global primary analysis of CheckMate 649, nivolumab plus chemotherapy demonstrated a clinically meaningful improvement in OS and PFS and higher response rate vs chemotherapy and an acceptable safety profile in Chinese patients. Nivolumab plus chemotherapy represents a new standard first-line treatment for Chinese patients with non-HER2-positive advanced GC/GEJC/EAC.
学科与关键词
- First-line nivolumab (NIVO) plus chemotherapy (chemo) vs chemo in patients with advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): CheckMate 649 Chinese subgroup analysis 2-year follow-upShen, L.; Bai, Y.; Lin, X.; Li, W.; Wang, J.; Zhang, X.; Pan, H.; Bai, C.; Bai, L.; Cheng, Y.; Zhang, J.; Zhong, H.; Ba, Y.; Hu, W.; Xu, R.; Guo, W.; Qin, S.; Yang, N.; Lu, J.; Chanaga, C. Amaya; Soleymani, S.; Liu, T.被引 1
- Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer: The ORIENT-16 Randomized Clinical TrialXu, Jianming*; Jiang, Haiping; Pan, Yueyin; Gu, Kangsheng; Cang, Shundong; Han, Lei; Shu, Yongqian; Li, Jiayi; Zhao, Junhui; Pan, Hongming; Luo, Suxia; Qin, Yanru; Guo, Qunyi; Bai, Yuxian; Ling, Yang; Yang, Jianwei; Yan, Zhilong; Yang, Lei; Tang, Yong; He, Yifu; Zhang, Liangming; Liang, Xinjun; Niu, Zuoxing; Zhang, Jingdong; Mao, Yong; Guo, Yingmei; Peng, Bo; Li, Ziran; Liu, Ying; Wang, Yan; Zhou, HuiJAMA, 2023, 330(21): 2064-2074.
- Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trialRha, Sun Young*; Oh, Do-Youn; Yanez, Patricio; Bai, Yuxian; Ryu, Min-Hee; Lee, Jeeyun; Rivera, Fernando; Alves, Gustavo Vasconcelos; Garrido, Marcelo; Shiu, Kai-Keen; Fernandez, Manuel Gonzalez; Li, Jin; Lowery, Maeve A.; Cil, Timucin; Cruz, Felipe Melo; Qin, Shukui; Luo, Suxia; Pan, Hongming; Wainberg, Zev A.; Yin, Lina; Bordia, Sonal; Bhagia, Pooja; Wyrwicz, Lucjan S.LANCET ONCOLOGY, 2023, 24(11): 1181-1195.被引 10
